Tesaglitazar
Tesaglitazar
Tesaglitazar (pronunciation: te-sag-li-ta-zar) is a pharmaceutical drug that was under development for the treatment of Type 2 diabetes and dyslipidemia. It belongs to the class of drugs known as glitazones, which are also referred to as thiazolidinediones.
Etymology
The name "Tesaglitazar" is derived from the class of drugs it belongs to, the glitazones, and its unique chemical structure. The prefix "Tesa-" is an arbitrary designation, while "-glitazar" is a common suffix for drugs in this class.
Pharmacology
Tesaglitazar is a dual Peroxisome proliferator-activated receptor (PPAR) agonist, meaning it activates both PPAR-alpha and PPAR-gamma receptors. These receptors play a crucial role in regulating lipid metabolism and glucose homeostasis, making them important targets for the treatment of conditions like Type 2 diabetes and dyslipidemia.
Development and Clinical Trials
The development of Tesaglitazar was carried out by AstraZeneca, a multinational pharmaceutical company. However, in 2006, the company announced the discontinuation of the drug's development due to concerns about its side effects and overall risk-benefit profile. Despite showing promise in early-stage clinical trials, later trials revealed potential risks associated with kidney function and heart health.
Related Terms
- Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose).
- Dyslipidemia: An abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood.
- Glitazones: A class of drugs used to treat diabetes mellitus type 2.
- Peroxisome proliferator-activated receptor (PPAR): A group of nuclear receptor proteins that function as transcription factors regulating the expression of genes.
- AstraZeneca: A British-Swedish multinational pharmaceutical and biopharmaceutical company.
External links
- Medical encyclopedia article on Tesaglitazar
- Wikipedia's article - Tesaglitazar
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski